LogoLogo
  • About Us
    • About Aurobindo
    • Vision / Mission
    • Milestones
    • R&D
    • Manufacturing
    • Management
      • Board of Directors
    • Our Presence
  • Our Business
    • APUSA
    • Europe
    • Growth Markets
    • ARV
      • Overview
      • Key facts about HIV/AIDS
      • Products
      • Global Partners
      • Gallery
      • Corporate Video
    • Apitoria (API)
    • Eugia (Speciality products)
    • Curateq (Biosimilars) / Peptide
  • Sustainability
    • ESG / Sustainability
      • ESG Profile
      • Sustainability Reports
      • BMW Reports
    • Social Accountability Standards
      • Social Compliance Certification
      • Sustainability of Social Accountability Standards
      • Human Rights Policy
      • Progressive Health and Safety Practices
      • Community Impact
      • Supply Chain Management
      • Supplier Code of Conduct
    • CSR
      • Aurobindo Pharma Foundation
      • CSR Policy
      • Annual Report
      • Gallery
      • Annual Action Plan
      • Impact Assessment Reports - CSR Projects
    • Access to Healthcare
      • PEPFAR program
  • Investors
    • Results, Reports & Presentations
      • Results Announcements
      • Annual Reports
      • Financials - Subsidiaries
      • Related Party Transactions
    • Shareholder Information
      • Shareholding Pattern
      • Buyback of shares
      • Share Performance
      • Financial Highlights
      • Notice of Board Meetings
      • General Meetings
      • Dividend Record
      • Scheme of Arrangements
      • Unpaid Dividend Account Details
      • Registrar and Share Transfer Agent
      • Contact Details for Investor Grievance Redressal
    • Corporate Governance
      • Board of Directors
      • Governance Policies
      • Code of Conduct
      • Code of Practices and Procedures for Fair Disclosure
      • Appointment and Resignation of Directors
      • Contact Details of KMPs
      • IR Contacts
    • Disclosures Under Regulation 46
      • Disclosures under Regulation 46 of the LODR
  • Media
    • Press Releases
    • Corporate Kit
  • Careers
    • Our Culture & Values
    • Life @ Aurobindo
    • Work with us / Oppurtunities
  • Contact Us

Investors

Commitment towards creating consistent value for our shareholders

2024 - 25
2023 - 24
2022 - 23
2021 - 22
2020 - 21
2019 - 20
2018 - 19
2017 - 18
2016 - 17
2015 - 16
2014 - 15
2013 - 14
2012 - 13
2011 - 12
2010 - 11
2009 - 10

Earnings Call Details

Q4FY25

Icon

Q3FY2025

Icon

Q2FY25

Icon

Q1FY25

Icon

Earnings News Release

PR-Q3 FY 2024-25

Icon

PR-Q2 FY 2024-25

Icon

PR-Q1 FY 2024-25

Icon

Earnings Presentation

Earnings Presentation-Q3 FY 2024-25

Icon

Earnings Presentation-Q2 FY 2024-25

Icon

Earnings Presentation-Q1 FY 2024-25

Icon

Financial Results

Q3 UFR 2024-25

Icon

Q2-UFR-2024-25-Corrigendum in Consolidated UFR

Icon

Q2 – UFR 2024-25

Icon

Q1 – UFR 2024-25

Icon
Footer Logo

REGISTERED OFFICE

Plot no. 2, Maitrivihar, Ameerpet, Hyderabad-500038, Telangana, India.

CORPORATE OFFICE

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City,
Raidurg Panmaktha, Rangareddy District,
Hyderabad - 500032, Telangana, India.

  • About Us
  • Our Business
  • Sustainability
  • Investors
  • Media
  • Careers
  • Contact Us
  • Privacy Policy
  • Site Map

© Copyright 2025 Aurobindo Pharma Limited. All rights reserved.